Effects of ACC Inhibitor on Lipid and Lipoprotein Metabolism
Stopped Poor enrollment
Conditions
- NASH (Nonalcoholic Steatohepatitis)
- NAFLD (Nonalcoholic Fatty Liver Disease)
Interventions
- DRUG: PF-05221304
- DRUG: Placebo
Sponsor
Columbia University
Collaborators